Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials

Launched by UNIVERSITY OF CHICAGO · May 23, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring new ways to encourage African American patients to participate in early-phase clinical trials for cancer treatments. The goal is to find out which outreach methods are most effective in increasing enrollment among underrepresented minorities. Both patients and their healthcare providers will be involved in the study, with some receiving these new outreach methods and others serving as a control group without any intervention.

To be eligible for the trial, patients need to be 18 years or older, identify as African American (including those who describe themselves as having more than one race), and have a scheduled visit with an oncologist at the study site. Patients with certain health issues, such as severe kidney problems or recent cancer treatment changes, will not be eligible. Participants can expect to learn more about clinical trials and possibly receive support to help them decide whether to take part in these important studies. This trial is currently recruiting participants, and everyone involved will contribute to improving access to cancer treatments for underrepresented groups in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria for Patient Subjects:
• • Aged 18 years or older
• • Self-described African American race (patients who self-describe as "more than one race" will be included)
• • Scheduled for new or consult oncology appointment at the study site
• • Scheduled for return outpatient oncology appointment at the study site with a biopsy or radiology encounter within 2 weeks prior to provider visit.
• • for prostate cancer patients: 2 or more increasing prostate specific antigen (PSA) values i the 6 months prior to visit
• • other patient identified by research team as potentially having a change in treatment prior to next outpatient oncology appointment at the study site
• Inclusion Criteria for Provider Subjects:
• • oncology provider at study site scheduled to see patients meeting criteria above
• Exclusion Criteria for Patient Subjects:
• • Estimated glomerular filtration rate (GFR) less than 30 ml/min/1.73m2 documented within last 2 months and without documented resolutions
• • Bilirubin greater than 3.0 ng/dl documented within last 2 months and without documented resolution
• • Initiated new anti-cancer therapy within last 2 months
• • Evaluated for possible enrollment/randomization in the last 2 months
• • Prior enrollment/randomization on this recruitment trial